Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

If all goes well at the FDA, Cal­lid­i­tas could cross the fin­ish line with its in­flam­ma­to­ry kid­ney dis­ease treat­ment Ne­fe­con next month. But Tra­vere Ther­a­peu­tics isn’t far be­hind — and on Mon­day, the for­mer Mar­tin Shkre­li com­pa­ny un­veiled some promis­ing piv­otal da­ta that may give Cal­lid­i­tas a run for its mon­ey.

Af­ter 36 weeks of treat­ment with Tra­vere’s sparsen­tan, pa­tients with a rare con­di­tion called IgA nephropa­thy saw a mean re­duc­tion in pro­tein­uria (ex­ces­sive pro­tein in the urine) of 49.8% from base­line, the com­pa­ny said. That com­pares to a mean re­duc­tion of 15.1% in a group of pa­tients who took Avapro, a cur­rent stan­dard of care (p<0.0001).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER